GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tellgen Corp (SZSE:300642) » Definitions » EV-to-FCF

Tellgen (SZSE:300642) EV-to-FCF : 29.12 (As of Jun. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Tellgen EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tellgen's Enterprise Value is ¥1,470.3 Mil. Tellgen's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was ¥50.5 Mil. Therefore, Tellgen's EV-to-FCF for today is 29.12.

The historical rank and industry rank for Tellgen's EV-to-FCF or its related term are showing as below:

SZSE:300642' s EV-to-FCF Range Over the Past 10 Years
Min: -200.66   Med: 97.98   Max: 1613.35
Current: 29.12

During the past 12 years, the highest EV-to-FCF of Tellgen was 1613.35. The lowest was -200.66. And the median was 97.98.

SZSE:300642's EV-to-FCF is ranked worse than
54.34% of 357 companies
in the Medical Devices & Instruments industry
Industry Median: 26.12 vs SZSE:300642: 29.12

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-24), Tellgen's stock price is ¥11.22. Tellgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.451. Therefore, Tellgen's PE Ratio for today is 24.88.


Tellgen EV-to-FCF Historical Data

The historical data trend for Tellgen's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tellgen EV-to-FCF Chart

Tellgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.60 269.17 -152.77 29.97 96.28

Tellgen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.06 36.25 47.71 96.28 36.29

Competitive Comparison of Tellgen's EV-to-FCF

For the Medical Devices subindustry, Tellgen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tellgen's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tellgen's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Tellgen's EV-to-FCF falls into.



Tellgen EV-to-FCF Calculation

Tellgen's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1470.255/50.492
=29.12

Tellgen's current Enterprise Value is ¥1,470.3 Mil.
Tellgen's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥50.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tellgen  (SZSE:300642) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Tellgen's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=11.22/0.451
=24.88

Tellgen's share price for today is ¥11.22.
Tellgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.451.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Tellgen EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Tellgen's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Tellgen (SZSE:300642) Business Description

Traded in Other Exchanges
N/A
Address
No. 115, Lane 572, Bibo Road, Building 1, Zhangjiang Hi-Tech Park, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Tellgen Corp manufactures and distributes in vitro diagnostic devices for detection of tumor. Its products include tumor marker, human papillomavirus, real time PCR, DNA methylation, autoimmune antibody, infectious disease and others. The company has developed products in the fields of tumor detection, cervical cancer screening, DNA methylation detection, male infertility and prenatal and postnatal care. Its products include tumor marker series products, human papillomavirus series products, Y chromosome microdeletion detection products, real time PCR, autoimmune antibody, and others.
Executives
Zhou Ai Guo Directors, executives
Chen Si Han Securities Affairs Representative

Tellgen (SZSE:300642) Headlines

No Headlines